Neoepitope detection of disease using protein arrays

A panel for use in detecting the presence of diseases, said panel comprising detection means for detecting a presence of at least one marker indicative of a specific disease.

A diagnostic tool for determining the efficacy of a pharmaceutical for treating a disease, said tool comprising:

• detection means for detecting a presence of at least one marker indicative of a specific disease;
• and
• analyzing means operatively connected to said detection means, said analyzing means for determining fluctuations in amount of marker present in said detection means, whereby fluctuations correlate to pharmaceutical efficacy.

A diagnostic tool for staging the progression of a disease, said tool comprising:

• detection means for detecting a presence of at least one marker indicative of disease recurrence;
• and
• analyzing means operatively connected to said detection means, said analyzing means for determining fluctuations in amount of marker present in said detection means, whereby fluctuations correlate to disease stage.

A method of determining efficacy of a pharmaceutical for treating a disease by:

• administering a pharmaceutical to a sample containing markers for a disease;
• detecting the amount of at least one marker of the disease in the sample;
• analyzing the amount of the marker in the sample, whereby the amount of marker correlates to response to therapy.

A method of staging a disease by:

• administering a therapy to a sample containing markers for a disease;
• detecting the amount of at least one marker of the disease in the sample;
• analyzing the amount of the marker in the sample, whereby the amount of marker correlates to disease stage.

An antigen array for use in detecting the presence of disease.

A method of treating disease by:

• detecting at least one marker of the disease in a sample;
• analyzing the type of the marker in the sample, whereby the type of marker correlates to a specific therapy.

Markers for gynecological disease selected from the list in Table 8.

An immuno-imaging agent comprising labeled antibodies, whereby said labeled antibodies are isolated and reactive to proteins overexpressed in vivo.

Diagnostic or prognostic markers for molecular pathology said markers being overexpressed or mutated proteins in tumor cells.